Literature DB >> 15127307

Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients.

R Artuch1, A Aracil, A Mas, E Monrós, M A Vilaseca, M Pineda.   

Abstract

We studied plasma and cerebrospinal fluid (CSF) concentrations of idebenone in five Friedreich ataxia patients on treatment with this antioxidant, and plasma and CSF ubiquinone-10 (Q (10)) concentrations in 15 controls. CSF idebenone concentrations were below the detection limit in 3 Friedreich ataxia patients and no association could be demonstrated between plasma and CSF idebenone values. Q (10) CSF concentrations (median: 2.25 nmol/L) were approximately 300 times lower than those of plasma (median: 0.77 micro mol/L). No correlation was observed between plasma and CSF Q (10) concentrations. A significantly positive correlation was observed between CSF total protein values (range 8.1 - 107.5 mg/dL; median: 29.5) and CSF Q (10) concentrations (Spearman test: r = 0.664; p = 0.01). Our findings suggest that less idebenone is distributed to the brain than to other tissues, although CSF does not appear to be an appropriate material for treatment monitoring of idebenone and other quinoid compounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15127307     DOI: 10.1055/s-2004-815830

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  7 in total

Review 1.  Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

Authors:  Julio C Rojas; Aleksandra K Bruchey; F Gonzalez-Lima
Journal:  Prog Neurobiol       Date:  2011-11-03       Impact factor: 11.685

Review 2.  Some observations upon biochemical causes of ataxia and a new disease entity ubiquinone, CoQ10 deficiency.

Authors:  John M Land; Simon J R Heales; Andrew J Duncan; Iain P Hargreaves
Journal:  Neurochem Res       Date:  2006-12-21       Impact factor: 3.996

3.  Biochemical diagnosis of coenzyme q10 deficiency.

Authors:  Delia Yubero; Raquel Montero; Rafael Artuch; John M Land; Simon J R Heales; Iain P Hargreaves
Journal:  Mol Syndromol       Date:  2014-07

4.  Treatment effect of coenzyme Q(10) and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease.

Authors:  Leslie Matalonga; Angela Arias; María Josep Coll; Judit Garcia-Villoria; Laura Gort; Antonia Ribes
Journal:  J Inherit Metab Dis       Date:  2013-12-18       Impact factor: 4.982

5.  Pharmacological Chaperones and Coenzyme Q10 Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease.

Authors:  Mario de la Mata; David Cotán; Manuel Oropesa-Ávila; Juan Garrido-Maraver; Mario D Cordero; Marina Villanueva Paz; Ana Delgado Pavón; Elizabet Alcocer-Gómez; Isabel de Lavera; Patricia Ybot-González; Ana Paula Zaderenko; Carmen Ortiz Mellet; José M García Fernández; José A Sánchez-Alcázar
Journal:  Sci Rep       Date:  2015-06-05       Impact factor: 4.379

6.  Coenzyme Q10 partially restores pathological alterations in a macrophage model of Gaucher disease.

Authors:  Mario de la Mata; David Cotán; Manuel Oropesa-Ávila; Marina Villanueva-Paz; Isabel de Lavera; Mónica Álvarez-Córdoba; Raquel Luzón-Hidalgo; Juan M Suárez-Rivero; Gustavo Tiscornia; José A Sánchez-Alcázar
Journal:  Orphanet J Rare Dis       Date:  2017-02-06       Impact factor: 4.123

Review 7.  Friedreich Ataxia: current status and future prospects.

Authors:  Katrin Bürk
Journal:  Cerebellum Ataxias       Date:  2017-04-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.